Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Subscribe To Our Newsletter & Stay Updated